Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Ambrx Biopharma Inc. (NYSE: AMAM) announced that its Chairman, President, and CEO, Feng Tian, Ph.D., will participate in two investor conferences in June. He will engage in a fireside chat at Cowen’s 3rd Annual Oncology Innovation Summit on June 2 at 11:30 AM PT and present at the JMP Securities Life Sciences Conference on June 16 at 11:00 AM PT. Interested parties can access webcasts through the company’s website, with replays available for 90 days. Ambrx focuses on Engineered Precision Biologics, advancing various therapeutic programs, including its lead product candidate ARX788.

SAN DIEGO--(BUSINESS WIRE)-- Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will participate in two upcoming investor conferences in June.

Cowen’s 3rd Annual Oncology Innovation Summit. Dr. Tian will participate in an analyst led fireside chat on Thursday, June 2 at 11:30 AM Pacific Time / 2:30 PM Eastern Time.

JMP Securities Life Sciences Conference. Dr. Tian will present on Thursday, June 16 at 11:00 AM Pacific Time / 2:00 PM Eastern Time.

Interested parties can access the live and pre-recorded webcasts for these conferences from the Investor Relations section of the company's website at www.Ambrx.com. The webcast replays will be available after the conclusion of the respective presentations for approximately 90 days.

About Ambrx Biopharma Inc. (Ambrx)

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, Ambrx has clinical collaborations with multiple partners, for drug candidates generated using Ambrx technology. For more information, please visit www.ambrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005400/en/

INVESTORS

Laurence Watts

Managing Director

Gilmartin Group, LLC.

619-916-7620

ir@ambrx.com

MEDIA

media@ambrx.com

Source: Ambrx, Inc.

FAQ

What is the schedule for Ambrx Biopharma's upcoming investor conferences in June 2023?

Feng Tian, CEO of Ambrx Biopharma, will participate in Cowen’s Oncology Innovation Summit on June 2 at 11:30 AM PT and present at the JMP Securities Life Sciences Conference on June 16 at 11:00 AM PT.

Where can I access the webcasts of Ambrx Biopharma's investor conferences?

The live and pre-recorded webcasts for Ambrx Biopharma's conferences will be available in the Investor Relations section of their website at www.ambrx.com.

What are Engineered Precision Biologics developed by Ambrx Biopharma?

Ambrx Biopharma develops Engineered Precision Biologics, including next-generation antibody drug conjugates, bispecifics, targeted immuno-oncology therapies, and novel cytokines for various therapeutic areas.

What is Ambrx Biopharma's lead product candidate?

Ambrx Biopharma's lead product candidate is ARX788, which is part of their robust portfolio of clinical and preclinical programs.

What is the focus of Ambrx Biopharma's clinical collaborations?

Ambrx Biopharma's clinical collaborations focus on drug candidates generated using their expanded genetic code technology platform.